Frank Bymaster has expertise in many areas of neuroscience and drug development for psychiatric diseases/disorders and has worked in these fields for over 45 years. Frank started research activities in 1970 at Eli Lilly and Co. and retired in 2003. During his time at Lilly, he contributed significantly to the discovery, pharmacological characterization, development and/or commercialization of Prozac (fluoxetine), duloxetine (Cymbalta), olanzapine (Zyprexa), atomoxetine (Strattera), and Symbyax (fluoxetine and olanzapine combination). He received the Lilly Research Laboratories award for innovative research 4 times. He has expertise in targeting drugs for major depressive disorder, schizophrenia, and ADHD. His expertise ranges from molecular pharmacology, in vivo disease models, and translational research. He also published over 150 papers (with 3500 citations), authored 25 U.S. patents and gave seminars throughout the world. After retirement from Lilly, Frank consulted and worked in biotech for Orexigen therapeutics Inc., Euthymics Bioscience Inc., and Neurovance Inc., investigating drugs for OCD, depression, and ADHD. Frank received a B.S. in pharmacy from Butler University in 1968 and a M.S. in pharmacology from Indiana University.
Chief Scientific Officer